Point of care estimation of B type natriuretic peptide levels in pediatric patients as a marker of cardiac disease

Vikram Bhaskar; Sumaira Khalil; Mani Raj; Prerna Batra

doi:10.18203/2349-3291.ijcp20242023

Authors

Vikram Bhaskar Department of Pediatrics, University College of Medical Sciences, Delhi, India
Sumaira Khalil Department of Pediatrics, University College of Medical Sciences, Delhi, India
Mani Raj Department of Pediatrics, University College of Medical Sciences, Delhi, India
Prerna Batra Department of Pediatrics, University College of Medical Sciences, Delhi, India

DOI:

https://doi.org/10.18203/2349-3291.ijcp20242023

Keywords:

Brain natriuretic peptide, Congestive heart failure, Critically sick children, Pneumonia, Point of care

Abstract

Background: Early recognition of heart disease in children can be challenging, because children often have a limited repertoire of presenting signs and symptoms. Primary purpose of our study was to compare the levels of BNP in cardiac and non-cardiac pediatric patients admitted in PICU.

Methods: The study was conducted prospectively on 45 patients admitted in PICU. The i-STAT POC device (Abbott, East Windsor, NJ) was used for BNP measurement. Patients aging 1 month to 12 years, were enrolled in three cohorts: 1) Cardiac cohort, consisting of patients presenting with features of heart failure, 2) non-cardiac patients admitted in PICU with respiratory distress, 3) Critically sick, non-cardiac patients (PELOD score >20) without respiratory distress.

Results: Mean BNP levels in cardiac cohort were 2273 (±1302) pg/ml, which were significantly higher than those observed in respiratory cohort (9655±1223 pg/ml) and other critical illness group (102±168). The area under the ROC curve for BNP was 0.956 and at a value of 837 pg/ml, BNP has a sensitivity of 93.3 and a specificity of 93% to correctly identify CHF in cardiac patients.

Conclusions: We concluded that BNP levels are significantly higher in cardiac patients and point of care BNP estimation can easily distinguish between cardiac and non-cardiac patients. We also found that though BNP is raised in respiratory illness as well, levels are not very high as compared to cardiac patients.

Metrics

Metrics Loading ...

References

Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339(5):321-8.

Yoshimura M, Yasue H, Okumura K, Ogawa H, Jougasaki M, Mukoyama M, et al. Different secretion pattern of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation. 1993;87(2):464-9.

Yandle TG. Biochemistry of natriuretic peptides. J Intern Med. 1994;235(6):561-76.

Nagagawa O, Ogawa Y, Itoh H, Suga S, Komatsu Y, Kishimoto I. Rapid transcriptional activation and early mRNA turnover of BNP in cardiocyte hypertrophy: evidence for BNP as an “emergency” cardiac hormone against ventricular overload. J Clin Invest. 1995;96(3):1280-7.

Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Ame Heart J. 1998;135(5):825-32.

Kalra PR, Anker SD, Coats AJS. Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin. Cardiovasc Res. 2001;51(3):495-509.

Koch A, Singer H. Normal values of B type natriuretic peptide in infants, children, and adolescents. Heart. 2003;89(8):875-78.

Hammerer-Lercher A, Geiger R, Mair J, Url C, Tulzer G, Lechner E, et al. Utility of N-terminal pro-B-type natriuretic peptide to differentiate cardiac diseases from noncardiac diseases in young pediatric patients. Clin Chem. 2006;52(7):1415-19.

Cohen S, Springer C, Avital A, Perles Z, Rein AJ, Argaman Z, et al. Amino-terminal pro-brain type natriuretic peptide: heart or lung disease in pediatric respiratory distress? Pediatrics. 2005;115(5):1347-50.

Evim MS, Ucar B, Kilic Z, Colak O. The value of serum N-terminal pro-brain natriuretic peptide levels in the differential diagnosis and follow-up of congestive cardiac failure and respiratory distress due to pulmonary aetiologies in infants and children. Cardiol Young. 2010;20(5):495-504.

Nevo I, Erlichman M, Algur N, Nir A. N-terminal pro B-type natriuretic peptide levels in infants and children with acute non-cardiac diseases. Isr Med Assoc J. 2011;13:420-4.

Costello JM, Goodman DM, Green TP. A review of the natriuretic hormone system's diagnostic and therapeutic potential in critically ill children. Pediatr Crit Care Med. 2006;7(4):308-18.

Charpentier J, Luyt CE, Fulla Y, Vinsonneau C, Cariou A, Grabar S, et al. Brain natriuretic peptide: a marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med. 2004;32(3):660-5.

Domico M, Liao P, Anas N, Mink RB. Elevation of brain natriuretic peptide levels in children with septic shock. Pediatr Crit Care Med. 2008;9(5):478-83.

Auerbach SR, Richmond ME, Lamour JM, Blume ED, Addonizio LJ, Shaddy RE, et al. BNP levels predict outcome in pediatric heart failure patients: post hoc analysis of the Pediatric Carvedilol Trial. Circ Heart Fail. 2010;3(5):606-11.

Selçuk M, Keskin M, Çınar T, Günay N, Doğan S, Çiçek V, et al. Prognostic significance of N-Terminal Pro-BNP in patients with COVID-19 pneumonia without previous history of heart failure. J Cardiovasc Thorac Res. 2021;13(2):141.